The core candidacy signal: focal hip cartilage damage

The clearest indicator for ChondroFiller hip injection is confirmed focal cartilage damage in the hip joint that has progressed significantly but has not yet reached complete end-stage loss. Specifically, the clinical target is an isolated ICRS Grade III or Grade IV defect — a lesion extending through more than half the cartilage depth, or reaching subchondral bone — surrounded by healthy cartilage borders that can anchor the collagen scaffold's repair environment. Patients with Kellgren–Lawrence Grade III or IV hip osteoarthritis also show evidence of benefit from the injectable approach, which means moderate-to-moderately-advanced wear is not a hard bar to candidacy.

The reason intervention at this threshold is clinically rational rather than premature lies in the hip's biology. Articular hyaline cartilage is avascular — it carries no blood supply and therefore cannot mount the healing response available to other injured tissues. Once a Grade III or IV lesion forms, it will not resolve on its own; the question is only how quickly it progresses.

This positions ChondroFiller in a treatment gap that many patients recognise from their own care journey. Below this threshold, watchful waiting and physiotherapy remain appropriate. Beyond it — at the point where cartilage is entirely absent — hip replacement becomes the main surgical option. Between those two points sits a large group of patients for whom NHS pathways offer limited middle ground. An injectable collagen scaffold, delivered as an outpatient appointment under ultrasound guidance, represents a distinct non-surgical option at precisely this stage.

Hip conditions that ChondroFiller can address

Four distinct clinical scenarios produce the focal hip cartilage lesion that ChondroFiller is designed to address.

Hip osteoarthritis — whether early focal wear or moderate-to-advanced Kellgren–Lawrence change — creates patches of thinned or exposed cartilage on the femoral head or acetabulum, typically surrounded by tissue that retains enough structural integrity to support repair.

Femoroacetabular impingement (FAI) works differently: abnormal bony contact between the femoral neck and the acetabular rim generates repetitive shear stress, stripping cartilage from discrete zones and producing focal lesions rather than diffuse thinning.

Sports and trauma injuries — including rotational loading, direct impact, and cartilage damage associated with labral tears — can cause acute or post-traumatic focal defects in otherwise healthy hip joints, often in younger or more active patients.

Age-related degenerative thinning, in the absence of a specific injury, produces gradual focal wear that crosses the Grade III/IV threshold without an obvious inciting event.

Across all four conditions, a contained defect with intact surrounding cartilage borders offers the most favourable repair environment. Defects up to 6 cm² fall comfortably within the established evidence base, and no hard upper size limit is stated in current clinical documentation. That shared characteristic — focal damage the hip cannot self-repair — is precisely where acellular matrix-induced chondrogenesis has its role: the collagen scaffold gels in situ and recruits the patient's own progenitor cells to support repair from within the lesion, without delivering cells directly.

Age, disease severity, and BMI: what does and doesn't rule you out

No upper age ceiling is documented for ChondroFiller hip injection candidacy, and the 'bone on bone' label that patients sometimes encounter on radiology reports does not automatically close the door. That phrase describes a radiographic finding — joint-space narrowing visible on imaging — and a joint's static appearance rarely captures the full clinical picture of how it loads, moves, and repairs.

What actually determines suitability is an assessment across four clinical lenses: physics (how the hip loads and distributes force), chemistry (the biological environment within the joint), biology (the patient's intrinsic repair potential), and timing (where the joint sits in its disease trajectory). Professor Lee uses this framework at consultation rather than applying age or scan appearance as a binary filter.

BMI enters directly through the physics lens. Higher body weight increases the compressive load across the articular surface, which influences both the repair environment and longer-term durability of any new tissue. No published hip-specific BMI threshold is defined for this treatment — body weight is weighed proportionately alongside joint mechanics, cartilage quality, and the patient's functional goals rather than applied as a pass-or-fail criterion. The clearest evidence-based steer available is on timing: intervening within the Grade III/IV window, before the joint deteriorates further, consistently creates more favourable biological conditions for repair than deferring until end-stage disease.

Treatment goals and procedural preferences that point toward ChondroFiller

Beyond anatomy, what a patient is hoping to achieve matters as much as what their imaging shows.

ChondroFiller promotes endogenous repair through a collagen scaffold that gels in situ and recruits the body's own cells — a biological process that unfolds over three to six months, not days. Patients who are primarily seeking an anti-inflammatory effect, or who expect symptom relief within the week, are unlikely to be well served by this pathway. Those who understand the repair window and are prepared to work within it are, in clinical experience, the more appropriate candidates.

The procedural profile is equally relevant. ChondroFiller is delivered as a single outpatient appointment under ultrasound guidance, with no general anaesthetic, no theatre admission, and no surgical wound to recover from. The session typically takes thirty to forty-five minutes. For patients in Lincolnshire managing work schedules, caring responsibilities, or simply unwilling or unable to travel to London for a surgical alternative, that is a meaningful practical advantage.

Patients whose principal aim is to defer or avoid hip replacement are particularly well aligned with ChondroFiller's preservationist position — it is not a palliative measure but an attempt to restore the joint's biological integrity at a stage when that remains possible.

Published evidence from the manufacturer's clinical evaluation report (Version 09, April 2025) shows IKDC scores improving by approximately 30 points over 12 months. That figure is a useful expectation anchor: meaningful, gradual, biologically driven improvement rather than immediate transformation.

Who ChondroFiller hip injection is not suitable for

Two absolute contraindications apply. An active infection within the hip joint rules out any injectable procedure until the infection has been fully resolved. And where articular cartilage is entirely absent — a genuinely end-stage joint — there is no biological substrate for the collagen scaffold to work with; at that point, hip replacement becomes the clinically appropriate conversation.

Beyond those hard stops, two further scenarios represent a functional mismatch rather than a medical exclusion. Diffuse cartilage loss spread across the entire hip joint surface, rather than a bounded focal defect, offers a less favourable repair environment; the scaffold is designed for contained lesions, not wholesale joint surface deterioration. Separately, patients primarily seeking rapid symptom relief — the kind that a corticosteroid injection may deliver within days — will find the repair-oriented nature of this treatment poorly matched to their expectations. The biological repair process unfolds over months, and that timeline is intrinsic to how the scaffold works, not a variable that can be shortened.

None of these criteria are reliably self-assessed. Whether a hip qualifies or is excluded is a clinical judgement based on imaging, examination findings, and individual treatment goals — confirmed at consultation, not from a patient checklist.

Getting assessed at Lincolnshire Hip

The assessment appointment is where candidacy is confirmed. Professor Paul Y. F. Lee reviews each patient's hip imaging alongside an examination of joint mechanics and treatment goals, working across the four clinical lenses — physics, chemistry, biology, and timing — before any recommendation is made.

Appointments are held locally in Grantham and Sleaford. No GP referral is needed: Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

What the consultation produces is a clear picture of the hip joint's current status — the grade and extent of cartilage loss, the mechanical environment in which that damage sits, and whether the biological conditions for scaffold-induced repair are present. Patients leave knowing whether ChondroFiller is the right next step, whether a different injection pathway fits the clinical picture better, or whether another conversation — about preservation surgery or hip replacement — is more appropriate at this stage.

Focal cartilage damage that is still contained within a bounded area of the hip joint offers more treatment options than diffuse end-stage loss. Earlier assessment preserves that clinical choice.